What is the recommended dosing regimen for isoprenaline (isoproterenol) in adults and pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Isoprenaline (Isoproterenol) Dosing

For shock in adults, initiate isoproterenol at 0.5 to 5 mcg/min as a continuous intravenous infusion, titrating to hemodynamic response; for bronchospasm, administer 10 to 20 mcg as an intravenous bolus injection. 1

Adult Dosing

Shock/Hypotension

  • Initial dose: 0.5 to 5 mcg/min IV infusion 1
  • Titration: Adjust based on heart rate, blood pressure, and cardiac output
  • Preparation: Add 1 mg (1 mL of 1:1000 solution) to 250 mL D5W = 4 mcg/mL concentration
  • Alternative preparation: 1 mg in 100 mL saline (1:100,000) at 30-100 mL/h (5-15 mcg/min), titrated to response 2
  • Monitoring: Continuous hemodynamic monitoring is essential; measure blood pressure and pulse every minute with continuous ECG monitoring 2

Bronchospasm (Acute)

  • Dose: 10 to 20 mcg IV injection 1
  • Note: This is a second-line therapy after beta-agonist inhalation therapy fails

Cardiac Arrhythmias (Bradycardia/Heart Block)

While not explicitly detailed in the FDA label for dosing, clinical practice uses similar infusion rates as for shock, starting at the lowest effective dose.

Pediatric Dosing

Safety and efficacy have not been established in pediatric patients. 1 However, when used:

Severe Asthma (Historical Use - Not Currently Recommended)

  • Dose range studied: 0.05 to 2.7 mcg/kg/min IV infusion 1
  • Critical warning: This has caused clinical deterioration, myocardial necrosis, congestive heart failure, and death in refractory asthmatic children 1
  • Risk factors: Acidosis, hypoxemia, concurrent corticosteroids, methylxanthines (theophylline, aminophylline) 1

If Used Despite Warnings

  • Low-dose approach: Start at 0.05 mcg/kg/min 3
  • Titration: Increase by 0.05 mcg/kg/min increments every 15-20 minutes based on response 3
  • Monitoring required: Continuous vital signs, frequent ECG, daily cardiac enzymes including CPK-MB 1
  • Alternative studied: 10 mcg/kg/h (approximately 0.17 mcg/kg/min) via large-volume nebulizer for severe asthma showed efficacy in one trial 4

Shock (Extrapolated from Adult Data)

  • Preparation by "Rule of 6": 0.6 × body weight (kg) = mg of isoproterenol diluted to 100 mL saline; then 1 mL/h delivers 0.1 mcg/kg/min 2

Critical Safety Considerations

Contraindications and Warnings

  • Do NOT administer simultaneously with epinephrine - both are direct cardiac stimulants and combined use may induce serious arrhythmias 1
  • Risk of lethal arrhythmias: Use extreme caution with continuous hemodynamic monitoring 2
  • Pregnancy: Avoid during second stage of labor; may cause uterine vasoconstriction and fetal anoxia 1

Drug Interactions Requiring Dose Adjustment

  • Potentiation: Tricyclic antidepressants, MAO inhibitors, levothyroxine, antihistamines (chlorpheniramine, diphenhydramine) increase isoproterenol effects 1
  • Antagonism: Beta-blockers (propranolol) antagonize effects; monitor and adjust accordingly 1

Monitoring Parameters

  • Continuous ECG monitoring
  • Blood pressure every 1-5 minutes during titration
  • Heart rate response
  • Cardiac output/index (if available)
  • Signs of myocardial ischemia (chest pain, ST changes)
  • In pediatrics: Daily CPK-MB if used 1

Common Pitfalls

  1. Starting too high: Always begin at the lowest recommended dose (0.5 mcg/min in adults)
  2. Inadequate monitoring: Arrhythmias can be lethal; continuous ECG is mandatory
  3. Use in pediatric asthma: This is largely abandoned due to cardiac toxicity risk; modern guidelines favor other therapies
  4. Concurrent epinephrine: Never combine these agents
  5. Extravasation: Can cause severe skin injury; ensure secure IV access 1

The evidence strongly supports starting at the lowest effective dose and titrating carefully with intensive monitoring, particularly given the narrow therapeutic window and significant cardiac toxicity risks.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.